Linked Life Data

16827799

Source:http://linkedlifedata.com/resource/pubmed/id/16827799

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2006-7-10
pubmed:abstractText
The insulin-like growth factor receptor type 1 (IGF1R) is suggested to play important roles in cancer cell growth through cross-talk with hormone receptors and growth factor receptors. However, its clinical significance in breast cancers in vivo is still unclear. We examined immunohistochemically the expression of IGF1R, phosphorylated-AKT (pAKT) and phosphorylated-ERK1/2 (pERK1/2) using tissue microarray slides containing 150 cases of primary breast carcinoma. Their mutual correlation and correlation with the status of hormone receptors epidermal growth factor receptor and human epidermal growth factor receptor type 2 were also investigated. IGF1R overexpression was detected in 71 cases (47%), and was correlated with lower nuclear grade (P = 0.03), positive estrogen receptor (ER) and/or progesterone receptor status (P = 0.002). pERK1/2 expression, detected in 53 cases (35%), was correlated with positive ER (P < 0.0001) and lower nuclear grade (P = 0.014). pAKT expression, detected in 88 cases (59%), was not correlated with nuclear grade, hormone receptors status or other clinical parameters. Of the 71 IGF1R-overexpressing tumors, pERK1/2 expression was detected in 27 (56%) of 48 ER-positive cases but in only four (17%) of 23 ER-negative cases (P = 0.022). In contrast, pAKT expression was constantly (64% or higher) detected irrespective of hormone receptor status in IGF1R-overexpressing breast cancers. Taken together, these findings suggest that IGF1R overexpression might activate pERK1/2 and pAKT in hormone receptor-positive breast cancer, but activate only pAKT in hormone receptor-negative breast cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1347-9032
pubmed:author
pubmed:issnType
Print
pubmed:volume
97
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
597-604
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:16827799-Adult, pubmed-meshheading:16827799-Aged, pubmed-meshheading:16827799-Aged, 80 and over, pubmed-meshheading:16827799-Breast Neoplasms, pubmed-meshheading:16827799-Extracellular Signal-Regulated MAP Kinases, pubmed-meshheading:16827799-Female, pubmed-meshheading:16827799-Humans, pubmed-meshheading:16827799-Immunohistochemistry, pubmed-meshheading:16827799-Middle Aged, pubmed-meshheading:16827799-Mitogen-Activated Protein Kinase 1, pubmed-meshheading:16827799-Mitogen-Activated Protein Kinase 3, pubmed-meshheading:16827799-Oncogene Proteins v-erbB, pubmed-meshheading:16827799-Phosphorylation, pubmed-meshheading:16827799-Proto-Oncogene Proteins c-akt, pubmed-meshheading:16827799-Receptor, IGF Type 1, pubmed-meshheading:16827799-Receptor, erbB-2, pubmed-meshheading:16827799-Receptors, Estrogen, pubmed-meshheading:16827799-Receptors, Progesterone, pubmed-meshheading:16827799-Tyrosine, pubmed-meshheading:16827799-Up-Regulation
pubmed:year
2006
pubmed:articleTitle
Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1.
pubmed:affiliation
Department of Surgery I, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
pubmed:publicationType
Journal Article